LLY - Eli Lilly and Co
A pharmaceutical giant riding the GLP-1 wave with blockbuster drugs Mounjaro and Zepbound for diabetes and obesity, transforming it into one of the most valuable companies on earth.
Finlify Score
69.0 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$1115.70
-0.65%
52W Range
$712.05 - $1292.65
Market Cap
$1.1T
-0.7%Compared to previous day
2026 Q1 Revenue
$19.8B
+2.6%Changes from last reporting quarter
2026 Q1 EPS
$8.00
Diluted shares
Analyst Rating
38 analysts in latest ratings feed
RSI
2.5
<40 oversold
2Y Range Position
74%
-13.7% from high / +78.9% from low
Beta
0.44
Relative to market benchmark
MACD
-9.98
MACD line -18.46 / signal line -8.48
Fundamental Trend
Growth 77.7Financial Health
Quality 82.0Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
WATCH69.0 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $19.8B+2.6% | $19.3B+9.6% | $17.6B+13.1% | $15.6B+22.2% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | $7.4B+11.4% | $6.6B+18.9% | $5.6B-1.4% | $5.7B+105.1% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
The Finlify signal for LLY is "WATCH," with an overall Finlify Score of 66.7 out of 100. This appears to reflect strong fundamental and financial quality scores, balanced by more moderate technical indicators.
Technical
The Relative Strength score of 63.5/100 suggests a generally favorable trend, though the Accumulation / Volume score of 34.3/100 indicates more subdued buying interest. The asset's RSI(14) is 46.9, appearing to be in a neutral range. While LLY has seen a 19.3% return over the past 60 days, it has experienced a -3.1% return over the last 20 days and is currently -6.5% from its 52-week high.
Fundamentals
LLY demonstrates strong fundamental characteristics, with a Fundamental Trend score of 77.7/100 and an excellent Financial Quality score of 82.0/100. The asset's valuation multiples, such as a P/E of 52.1x, P/B of 38.3x, and P/S of 16.5x, appear elevated relative to some market averages. With a Beta of 0.5, LLY may exhibit lower volatility compared to the broader market, and it offers a Dividend Yield of 0.60%.
Macro Context
The current macro environment, characterized by CPI YoY at 3.7% and Core PCE YoY at 3.3%, suggests persistent inflation, while the 10Y Treasury Yield at 4.7% indicates a higher interest rate environment which could impact growth stock valuations. The positive yield spread of 0.5% (10Y-2Y) may suggest a less immediate recessionary concern, potentially providing a stable backdrop for defensive sectors like pharmaceuticals.
Key Risks
- Elevated valuation multiples (P/E of 52.1x, P/B of 38.3x, P/S of 16.5x) may suggest limited upside potential or increased sensitivity to market corrections.
- Upcoming earnings on 2026-08-05 could introduce significant price volatility.
- A moderate Accumulation / Volume score of 34.3/100 may indicate a lack of strong institutional buying pressure.